OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Proposed [GID-HST10022] Expected publication date: TBC
Search results
155 results
-
-
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Proposed [GID-HST10019] Expected publication date: TBC
-
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]
Proposed [GID-HST10034] Expected publication date: TBC
-
VTS-270 for treating Niemann-Pick type C1 (ID1267)
Proposed [GID-HST10020] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Proposed [GID-HST10039] Expected publication date: TBC
-
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
Proposed [GID-HST10037] Expected publication date: TBC
-
Avalglucosidase alfa for treating Pompe disease [ID3737]
Proposed [GID-HST10030] Expected publication date: TBC
-
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818
Proposed [GID-HST10040] Expected publication date: TBC
-
Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]
Proposed [GID-HST10038] Expected publication date: TBC
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 20 April 2021.
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 20 April 2021.
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 April 2021.
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 April 2021.
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 26 April 2021.
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Proposed [GID-TA10741] Expected publication date: TBC
-
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]
Proposed [GID-TA10691] Expected publication date: TBC
-
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Proposed [GID-TA10694] Expected publication date: TBC
-
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]
Proposed [GID-TA10698] Expected publication date: TBC
-
Etranacogene dezaparvovec for treating haemophilia B [ID3812]
Proposed [GID-TA10699] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]
Proposed [GID-TA10702] Expected publication date: TBC
-
Eptinezumab for preventing migraine [ID3803]
Proposed [GID-TA10677] Expected publication date: TBC
-
Remimazolam for general anaesthesia [ID3796]
Proposed [GID-TA10679] Expected publication date: TBC
-
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]
Proposed [GID-TA10680] Expected publication date: TBC
-
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Proposed [GID-TA10682] Expected publication date: TBC
-
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]
Proposed [GID-TA10684] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Proposed [GID-TA10683] Expected publication date: TBC
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Proposed [GID-TA10536] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Proposed [GID-TA10758] Expected publication date: TBC
-
Sotagliflozin for treating type 2 diabetes [ID1657]
Proposed [GID-TA10665] Expected publication date: TBC
-
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Proposed [GID-TA10598] Expected publication date: TBC
-
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Proposed [GID-TA10685] Expected publication date: TBC
-
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Proposed [GID-TA10722] Expected publication date: TBC
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Proposed [GID-TA10700] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Proposed [GID-TA10716] Expected publication date: TBC
-
Mepolizumab for treating hypereosinophilic syndrome [ID3749]
Proposed [GID-TA10755] Expected publication date: TBC
-
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)
Proposed [GID-TA10279] Expected publication date: TBC
-
Tocilizumab for treating systemic sclerosis (ID1396)
Proposed [GID-TA10346] Expected publication date: TBC
-
Intravenous zanamivir for treating influenza in hospital [ID1196]
Proposed [GID-TA10298] Expected publication date: TBC
-
Remdesivir for treating COVID-19 [ID3808]
Proposed [GID-TA10721] Expected publication date: TBC
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Proposed [GID-TA10668] Expected publication date: TBC
-
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Proposed [GID-TA10604] Expected publication date: TBC
-
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
Proposed [GID-TA10637] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Proposed [GID-TA10638] Expected publication date: TBC
-
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]
Proposed [GID-TA10767] Expected publication date: TBC
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Proposed [GID-TA10773] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
Proposed [GID-TA10775] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Proposed [GID-TA10776] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Proposed [GID-TA10778] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Proposed [GID-TA10779] Expected publication date: TBC